Sage Therapeutics Shifts Focus After Ending Biogen Partnership
Sage Therapeutics Ends Collaboration on SAGE-324
Sage Therapeutics, Inc. (NASDAQ: SAGE) recently announced a significant change in its strategy as its partner, Biogen (NASDAQ: BIIB), has chosen to terminate its rights to the investigational neurology candidate, SAGE-324. This decision comes after a phase II study aimed at treating essential tremor, which did not achieve its primary endpoint in a review conducted earlier this year.
This collaboration termination will become effective on a date specified by the company. Following this change, Sage Therapeutics is set to regain full ownership and rights related to SAGE-324, with plans to investigate other potential uses for the candidate in the future.
This year has not been particularly kind to Sage Therapeutics, as its shares have seen a substantial downturn, plummeting 66.9% to date, contrasting sharply with the overall industry decline of merely 1.9%.
Details of the Licensing Agreement with Biogen
The partnership between Sage Therapeutics and Biogen, established to lead the clinical development of SAGE-324, bore mixed results. In July, both companies revealed the top-line data from the phase II KINETIC 2 study, which was designed to assess the drug's effectiveness as a treatment for essential tremor. Unfortunately, the data failed to show a statistically significant dose-response relationship regarding the study’s primary objective.
Disappointed by these results, both Sage Therapeutics and Biogen agreed to halt any further clinical development of SAGE-324 for this specific indication. The focus has now shifted towards SAGE's other ongoing projects.
Current Developments in Sage Therapeutics' Portfolio
While SAGE-324's journey takes a pause, Sage Therapeutics is actively marketing Zurzuvae (zuranolone), an innovative treatment developed in conjunction with Biogen. This medication has gained traction as the first oral treatment approved for postpartum depression in adults, receiving its FDA approval in a recent review.
Launched commercially in a prior month, Zurzuvae holds significant promise in addressing a critical area of mental health treatment. The two companies share the financial responsibilities arising from Zurzuvae's commercialization in the United States, while Biogen handles sales in several international markets, paying royalties back to Sage for this innovative therapy.
Both firms are working diligently to position Zurzuvae as a primary treatment option for women experiencing postpartum depression. However, the FDA recently issued a complete response letter concerning a new drug application for zuranolone aimed at major depressive disorder, stating that the existing data did not substantiate effective treatment claims, prompting additional clinical studies.
Stock Performance and Future Prospects
At present, Sage Therapeutics holds a Zacks Rank of #3, indicating a Hold recommendation. Investors are keen on how the company will adapt and pivot following this termination.
In the biotech sector, some stocks show strong momentum and rank at #1 (Strong Buy). Noteworthy mentions include Krystal Biotech, Inc. (NASDAQ: KRYS) and Fulcrum Therapeutics, Inc. (NASDAQ: FULC).
Over the preceding two months, estimates for Krystal Biotech's earnings per share for 2024 have surged, with projections increasing from $2.09 to $2.38. Additionally, their 2025 earnings forecasts have escalated significantly. Year-to-date, shares of Krystal Biotech have experienced a robust 43.8% growth.
For Fulcrum Therapeutics, the outlook for 2024 has improved with losses per share estimates narrowing recently, which bodes well for the company's financial resilience. Despite an overall plunge of 40.8% in the year to date, Fulcrum has managed to beat estimates across recent quarters.
Looking Ahead for Sage Therapeutics
The shift in strategy following the termination of the collaboration with Biogen signifies an important turning point for Sage Therapeutics. With renewed focus on SAGE-324 and the successful commercialization of Zurzuvae, the company is poised to explore various pathways as it navigates through future developments in mental health treatments.
Frequently Asked Questions
What led to the termination of the partnership between Sage and Biogen?
The partnership was terminated after the phase II study of SAGE-324 for treating essential tremor failed to meet its primary endpoint.
What is Sage Therapeutics' main current product on the market?
Sage's leading product in the market is Zurzuvae (zuranolone), an oral treatment approved for postpartum depression.
How has Sage Therapeutics' stock performed this year?
The stock has seen a significant decline of 66.9% this year, contrasting with the industry average decrease of 1.9%.
What are Sage's plans for SAGE-324 moving forward?
Sage intends to explore other indications for SAGE-324 after regaining full ownership of the therapy.
What is the current outlook for Zurzuvae?
Zurzuvae is being positioned as a first-line therapy for postpartum depression, with Sage and Biogen aiming to establish it as a standard treatment.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Avenue Therapeutics Appoints Executives with Equity Awards
- Fairholme Focused Income Fund Declares Important Dividend Update
- Duke Energy Launches Extensive Recovery Operations After Helene
- 111, Inc. Secures Compliance Period After Nasdaq Notification
- Pliant Therapeutics Adjusts Bylaws in Response to Legal Changes
- Jacobs Completes Spin-off and Merger, Focuses on Growth
- Jacobs Successfully Completes Merger and Spin-off, Strengthens Focus
- Poseida Therapeutics Advances with P-BCMA-ALLO1 Clinical Success
- Eterna Therapeutics Partners with Factor Bioscience for New Developments
- Poseida Therapeutics Achieves Remarkable Phase 1 Results with P-BCMA-ALLO1
Recent Articles
- Class Action Lawsuit Opportunities for Allarity Investors Unveiled
- Seize Your Chance: Join the Class Action Against Coinbase Today!
- In-depth Investigation of Visa Inc. by Leading Law Firm
- Chanson International's Strategic Focus on Growth Amid Challenges
- Fannie Mae's Annual Impact on Housing Accessibility
- TransMedics Enhances Employee Incentives with Stock Grants
- AllianceBernstein National Municipal Income Fund's Q3 Earnings Report
- Vor Biopharma Faces Challenges as Stock Hits Yearly Low
- Babson Capital Corporate Investors Stock Reaches New Heights
- Next Technology's Bold Bitcoin Acquisition Strategy Unveiled
- Amentum Holdings Expands Leadership with New COO Appointment
- Musalem Advocates for Gradual Reduction in Interest Rates
- Air Canada Faces $250,000 Penalty for Iraqi Airspace Violations
- Rail Delays Impacting U.S. Agricultural Exports to Mexico
- Biden Remains Firm on U.S. Steel Ownership amid Nippon Bid
- Exploring Promising Renewable Energy Stocks for Growth
- New York's Cannabis Market Expected to Surge to $1 Billion
- Understanding Nvidia's Share Decline Amid Market Shifts
- Blizzard's Ambitious Third Attempt at a StarCraft Shooter Development
- Investigation Launched into Block, Inc. for Potential Violations
- Nintendo Emphasizes Unique Identity Amidst Console Wars
- BlackBerry Faces Challenges but Eyes Path to Future Growth
- Economic Trends Drive Market Movements and Innovations
- Reviving Interest in the Uranium Sector for Growth
- Linde's Impressive 5-Year Growth: A $100 Investment Worth Today
- Transforming $1000 Into Over $8600: The ASML Growth Story
- EOG Resources Stock Analysis: Critical Support at $118
- Market Sentiment Shifts: Understanding Newmont's Short Interest
- Fidelity Life Association's Credit Ratings Affirmed by AM Best
- Analyzing Market Sentiment: A Look at DocuSign's Short Interest
- Analyzing Recent Trends in Curtiss-Wright's Short Interest
- Rocket Lab Stock Soars: Is Now the Time to Invest?
- Axonics Gains Ongoing Support with TGA Approval for R20 SNM System
- Teamsters Local 251 Votes to Authorize Strike for Justice
- Monroe Capital Soars to New Heights with 52-Week High
- Seres Therapeutics Faces Shareholder Backlash Over Nestlé Bid
- S&W Seed Co Moves Forward with Strategic Stock Restructuring
- Citi Implements New Controls to Address Employee Misconduct Concerns
- Volkswagen Faces Challenges, Reduces Sales and Profit Outlook
- Atos SE Gains Strong Backing for Critical Safeguard Proposal
- Important Legal Update Regarding Arbor Realty Trust, Inc.
- North Slope Borough Secures AA+ Rating: A Stable Future Ahead
- Deadline Approaches for Five Below, Inc. Investors in Class Action
- Understanding Lamb Weston Holdings Inc.'s Earnings Insights
- Understanding Bumble Inc.'s Class Action Lawsuit Insights
- Quidax Unveils $125K Crypto Innovation Pitch with Moonshot
- Citi Reaffirms Optimistic Outlook for GN Store Nord with DKK225 Target
- Analyzing the Recent Movements of the Nasdaq 100 Index
- United Community Banks, Inc. Preparing for Q3 2024 Earnings Call
- Ozan Ardic's Inaugural Concert Tour Set to Inspire Canada